Fine‐needle aspiration for proteomic study of tumour tissues

Giusti, Laura; Iacconi, Pietro; Lucacchini, Antonio

doi:10.1002/prca.201000091

Cited by 3 publications

(2 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Collection of these specimens by means of surgical resections or sometimes even by core biopsies are infeasible given the size and anatomical location of metastatic lesions, and the desire to avoid unnecessary invasive procedures. Fine-needle aspiration (FNA), which utilizes lower profile needles as compared with core biopsies, offers a minimally-invasive alternative to sample collection and reduces the risk of bleeding and injury 36 . To ensure maximal clinical utility, we sought to determine the feasibility of performing mass response measurements using these low-input FNA specimens, which often yield only tens of thousands of single cells for downstream analysis.…”

Section: Resultsmentioning

confidence: 99%

A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements

Kimmerling¹,

Stevens²,

Ölçüm³

et al. 2022

Commun Biol

View full text Add to dashboard Cite

Functional precision medicine offers a promising complement to genomics-based cancer therapy guidance by testing drug efficacy directly on a patient’s tumor cells. Here, we describe a workflow that utilizes single-cell mass measurements with inline brightfield imaging and machine-learning based image classification to broaden the clinical utility of such functional testing for cancer. Using these image-curated mass measurements, we characterize mass response signals for 60 different drugs with various mechanisms of action across twelve different cell types, demonstrating an improved ability to detect response for several slow acting drugs as compared with standard cell viability assays. Furthermore, we use this workflow to assess drug responses for various primary tumor specimen formats including blood, bone marrow, fine needle aspirates (FNA), and malignant fluids, all with reports generated within two days and with results consistent with patient clinical responses. The combination of high-resolution measurement, broad drug and malignancy applicability, and rapid return of results offered by this workflow suggests that it is well-suited to performing clinically relevant functional assessment of cancer drug response.

show abstract

Section: Resultsmentioning

confidence: 99%

A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements

Kimmerling¹,

Stevens²,

Ölçüm³

et al. 2022

Commun Biol

View full text Add to dashboard Cite

show abstract

“…e number of cells obtained via FNAB is exceptionally low and proteomic analysis of the material in the aspirated sample is extremely challenging. us, only a limited number of studies exist on proteomic pro ling of FNAB [1][2][3][4][5]. In a study by Rapkiewicz et al [6], ne-needle aspiration samples from breast tumors were analyzed by quantitative protein microarray technology.…”

Section: Introductionmentioning

confidence: 99%

Proteomic analysis of low quantities of cellular material in the range obtainable from scarce patient samples

Parapatics¹,

Huber²,

Lehmann³

et al. 2015

JIOMICS

View full text Add to dashboard Cite

e application of proteomics to patient material is increasingly widespread, however, a major shortcoming still are the number of cells or protein material that can be obtained. is study explores the lower limit of cell numbers that can be successfully analysed by liquid chromatography mass spectrometry to determine the protein expression pro le that is speci c to, and indicative of, the investigated cell type. e aim was to analyse an equivalent quantity of cellular material that can be obtained from, e.g., a ne-needle aspiration biopsy (FNAB). Fi een thousand and 30,000 cells from adherent (HEK293) and suspension (U937) cell lines were lysed under two di erent conditions: a 'native' and a denaturing bu er. To extend the study to clinical material, human whole PBMCs were also lysed under identical conditions. Proteins from 5,000 and 10,000 cells were analysed by both 1D and 2D-LC-MSMS on an LTQ Orbitrap XL mass spectrometer. In total, 3,219; 1,693 and 659 unique proteins were identi ed from HEK293, U937 and total PBMCs, respectively. Additionally, an iTRAQ 4-plex experiment was performed to determine the relative quantity of the proteins in the three cell types. In this study, we show that it is feasible to obtain a deep, yet cellspeci c protein pro le from a very low number of cultured and primary cells. is advancement will enable proteomic-pro ling of cellular material from ne needle aspiration biopsies that ultimately can assist cytopathologists in the diagnosis of disease.

show abstract

Lymph Nodes

Wieczorek¹,

Wakely²

2014

Cytology

View full text Add to dashboard Cite

Fine‐needle aspiration for proteomic study of tumour tissues

Cited by 3 publications

References 49 publications

A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements

A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements

Proteomic analysis of low quantities of cellular material in the range obtainable from scarce patient samples

Lymph Nodes

Contact Info

Product

Resources

About